EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera
This article was originally published in The Pink Sheet Daily
After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.
You may also be interested in...
Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.
UniQure’s Glybera (alipogene tiparvovec) has become the first gene therapy to be approved for commercialization in the 27-nation European Union, marking a major step towards making such medicines available for treating rare diseases that have a high unmet medical need.
After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?